Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Reports Q1 2025 Results and Clinical Updates
Summary
Terns Pharmaceuticals, Inc. reported its financial results for the first quarter of 2025, showing a net loss of $23.9 million. The company initiated dose expansion in the Phase 1 CARDINAL trial for its CML treatment and expects additional safety and efficacy data in the fourth quarter of 2025. The Phase 2 FALCON trial for obesity is progressing well, with top-line 12-week weight loss data expected in the fourth quarter of 2025. The company's cash position was $334.3 million as of March 31, 2025, with funds expected to support planned operating expenses into 2028.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement